Tempus AI (Nasdaq: TEM), an artificial intelligence (AI)-based precision medicine company, is expanding its engagement with global healthcare investors.

Tempus AI announced that its founder and Chief Executive Officer (CEO), Eric Lefkofsky, will participate in a fireside chat at the 'Morgan Stanley 24th Annual Global Healthcare Conference,' to be held in New York at 8:30 a.m. (U.S. Eastern Time) on September 15.

The conference is one of the leading investment gatherings where global healthcare companies and institutional investors come together. Instead of a separate formal presentation, Tempus AI plans to explain its business strategy, growth direction, and key issues surrounding the healthcare AI market in a fireside chat format.

The conversation will be broadcast live via audio webcast. As a result, investors who do not attend in person can directly follow the remarks of Tempus AI's management online.

◆ Data virtuous cycle as core competitive strength

Tempus AI is a technology company focused on advancing precision medicine through the use of AI in healthcare. It has built a large-scale multimodal medical data library and a data- and AI-based platform that enables its use in actual clinical settings.

Specifically, the company analyzes clinical and molecular data for individual patients to help physicians make personalized treatment decisions. It is also expanding a business model that applies AI and medical data to drug discovery and development as well as to the selection of appropriate therapies.

The company's key emphasis is a 'virtuous cycle structure' in which accumulated medical data is reused for patient care. Data obtained from the treatment of existing patients is analyzed and provided to physicians as tools and information that can be applied to the diagnosis and treatment choices of future patients.

◆ Combination of generative AI and precision medicine draws investor attention

In the global healthcare industry, moves to combine generative AI with precision medicine, genomic analysis, and integrated medical data are accelerating. Accordingly, how Tempus AI explains the growth strategy of its data-driven medical AI business and its future expansion plans at this Morgan Stanley conference is expected to be a major focus for investors.

[This article was reconstructed into a news format with the assistance of AI based on official disclosure materials released by Tempus AI. Event schedules and participation methods are subject to change depending on circumstances of the company or the organizers, and this information is not intended to recommend the purchase or sale of any specific stock or to advise on investment decisions. Investment decisions and any resulting responsibility rest with the investor.]